WhenHypomaniaWasMissedBeforeTheSSRI.

The under-recognition of bipolar disorder in primary care and even in psychiatric settings is well-documented in the literature. Published estimates place the proportion of bipolar patients initially diagnosed with unipolar depression in the range of 40% or higher, with average time-to-correct-diagnosis measured in years. The mechanism is consistent across cases and clinical settings.

Four intersecting components drive the pattern:

• Patients present in the depressive phase. The depressive episodes are the ones that produce suffering, impair function, and motivate help-seeking. The hypomanic episodes do not generally feel like illness — they feel like a good stretch. Patients show up asking for relief from depression, not volunteering a history of elevated moods.
• Hypomania is not always recognized as pathology. Bipolar II hypomania, in particular, can be subtle — increased energy, reduced sleep need, elevated mood, increased productivity, increased goal-directed activity — without the full manic impairment. The patient experiences it as “a really good few weeks” and the clinician, if not specifically asking, never identifies it.
• Screening instruments are underused. The Mood Disorder Questionnaire, the HCL-32, the Composite International Diagnostic Interview — each is validated and brief. None is universally administered in primary care or even in much psychiatric evaluation. Without the structured screen, the diagnosis depends entirely on what the patient happens to volunteer.
• Time pressure on initial visits. Primary-care depression screens (PHQ-9) capture depressive symptoms reliably but do not systematically screen for hypomania. A busy primary-care visit attaches a depression label and writes for an SSRI without the longer conversation needed to rule out bipolarity.

The pattern is not mysterious. A young adult presents with a depressive episode, receives an SSRI without anyone asking in detail about prior elevated-mood periods, experiences a manic switch several weeks later, and ends up hospitalized with the correct bipolar diagnosis established only after the crisis. The cases that become malpractice claims are the ones where the screening documentation shows the question simply was not asked.

The American Psychiatric Association practice guidelines, the Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines, and general psychiatric practice standards all emphasize screening for bipolar disorder before initiating antidepressant treatment in a patient presenting with depression. Core requirements:

• Detailed history of prior mood episodes. Specific questions about periods of elevated, irritable, or expansive mood lasting at least four days; reduced sleep need; increased energy; increased goal-directed activity; inflated self-esteem; racing thoughts; increased risk-taking. Family report can supplement patient report.
• Validated screening instruments where indicated. The Mood Disorder Questionnaire (MDQ), HCL-32, or equivalent. Brief, validated, and meaningful for documentation.
• Family history. First-degree relatives with bipolar disorder dramatically increase the pre-test probability. A positive family history warrants particularly careful bipolar screening.
• Age-of-onset considerations. Early-onset depression (before age 25), treatment-resistant depression, and postpartum mood episodes are each associated with elevated bipolar prevalence and warrant heightened screening.
• Careful evaluation of prior antidepressant responses. Prior paradoxical responses to antidepressants (activation, irritability, insomnia after initiation) suggest bipolar biology.
• Mood-stabilizer-first approach where bipolar is suspected. When the screen raises bipolar concern, initial treatment with a mood stabilizer (lithium, valproate, lamotrigine, quetiapine) rather than antidepressant monotherapy is the standard.

Compare what the record shows against what the standard requires. A chart that documents only “patient presents with depression, started on sertraline” without any recorded inquiry into hypomanic history is the clearest version of this breach. A chart that documents a family history of bipolar disorder and still proceeds with antidepressant monotherapy is another. Florida malpractice cases for SSRI-induced mania are built on exactly these documentation gaps.

The phenomenon of antidepressant-induced manic switch is well-documented in psychiatric literature. The risk is not theoretical — it is observed, reproducible, and recognized in official diagnostic frameworks (the DSM-5 has specific criteria for substance/medication-induced mood disorder).

Mechanism and risk profile:

• Affected medications. SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), SNRIs (venlafaxine, duloxetine), tricyclics (highest risk historically), bupropion (lower risk), MAOIs. The risk is present across antidepressant classes, though magnitude varies.
• Higher risk populations. Bipolar I greater than Bipolar II, early-onset depression, family history of bipolar disorder, prior paradoxical antidepressant responses, younger patients.
• Timing. Typically weeks to months after initiation or dose increase, though can occur at any point.
• Protective co-treatment. Concurrent mood stabilizer (lithium, valproate, lamotrigine, second-generation antipsychotic) reduces but does not eliminate the risk. This is why monotherapy antidepressant in a known or suspected bipolar patient is contraindicated.
• Consequences of the manic episode. Psychiatric hospitalization (often involuntary), financial harm from impulsive spending, relationship damage, employment loss, physical injury from risky behavior (reckless driving, unsafe sex, violence), and elevated suicide risk during the transition back into depression.

Keep in mind that not every case of SSRI-induced mania is malpractice. If the provider screened appropriately and the patient’s history was negative, the subsequent manic episode is an unfortunate and relatively rare outcome, not a breach. The malpractice analysis turns on what screening occurred before prescribing, not on whether the mania occurred after.

The injury in an SSRI-induced mania case is not the diagnosis — the injury is what the manic episode did. Courts and fact-finders in malpractice cases look at concrete harm, and in these cases the concrete harm is varied and often substantial:

• Psychiatric hospitalization. Inpatient psychiatric admission, often involuntary under Florida’s Baker Act. Typical stay is days to weeks. Records the hospitalization itself, any medication changes, the diagnostic correction, and any consequences of the admission (employment notification, insurance disputes).
• Financial harm. Impulsive spending during mania is a recognized feature. Credit card debt, business decisions, gifts given, gambling losses, investments made on manic judgment. The damage is concrete and documented.
• Relationship damage. Divorce filings initiated during mania, custody disputes triggered by manic behavior, affairs, friendships burned, family relationships strained. Some consequences are reversible, many are not.
• Employment loss. Manic-episode behavior at work — inappropriate emails, erratic decisions, absenteeism, interpersonal conflict — can produce termination. The subsequent depression and hospitalization may compound the employment loss.
• Physical injury. Reckless driving, unsafe sex, altercations, self-harm during mania or the subsequent depression.
• Suicide risk. The post-manic depressive episode carries elevated suicide risk, particularly when compounded by the consequences of the manic behavior (shame, damage, broken relationships).

In fatal cases involving suicide, Florida wrongful death damages under the Wrongful Death Act apply — for spouse, minor children, and dependent parents. The causation analysis requires expert psychiatric testimony connecting the prescribing failure, the manic episode, the depressive consequence, and the suicide.

These cases are, in some ways, the most document-dependent of the wrong-diagnosis categories — the case turns almost entirely on what the prescribing provider’s note says and does not say. Key evidentiary sources:

• The prescribing visit note. Exactly what was documented about the patient’s mood history, the presence or absence of hypomanic screening, whether a validated instrument was used, the reasoning for the diagnosis and prescription.
• Prior mental-health records. Any prior episodes that, in retrospect, can be identified as hypomanic — even if not labeled as such at the time. This establishes what the prescribing provider should have been able to elicit.
• Family history documentation. Any family history of bipolar disorder recorded or obtainable.
• The hospitalization that confirmed the diagnosis. Baker Act records, inpatient psychiatric evaluation, the diagnostic formulation, medication changes, and the explicit connection (where documented) between antidepressant use and the manic episode.
• Real-world harm documentation. Financial records (credit card statements, bank records, loss documentation), legal records (divorce filings, custody proceedings), employment records, medical records of physical injuries during mania.
• Post-discharge psychiatric records. Ongoing treatment showing the diagnosis and the longer-term impairment.

Florida Statute § 766.102 requires a corroborating expert affidavit before filing. The expert in a bipolar misdiagnosis case is a board-certified psychiatrist, typically one with experience in both outpatient prescribing and inpatient management of mood disorders.

Damages in an SSRI-induced mania case reflect the specific harm the manic episode produced. Cases with substantial documented financial harm, employment loss, or physical injury drive different valuations than cases where the manic episode resolved with inpatient treatment and minimal external consequences.

• Past medical expenses for psychiatric hospitalization, subsequent outpatient care, medication, and therapy.
• Future medical expenses for ongoing psychiatric management of the now-correctly-diagnosed bipolar disorder.
• Lost earnings during hospitalization and recovery, lost earnings from any employment terminated as a consequence of manic behavior.
• Lost earning capacity where permanent psychiatric or cognitive impairment resulted.
• Pain and suffering, including the suffering of the manic episode, the subsequent depression, and any permanent psychiatric consequences.
• Loss of consortium for spouse, which may be particularly relevant where the manic episode precipitated divorce or permanent relationship damage.
• Concrete financial loss from manic-episode decisions, where the causal chain is established.

Florida no longer caps non-economic damages in medical malpractice cases after North Broward Hospital District v. Kalitan, 219 So. 3d 49 (Fla. 2017).

Florida Statute § 95.11(4)(b) governs medical malpractice limitations: two years from discovery of the injury, four-year outer limit, seven years in cases of fraud or concealment. Wrongful death claims (including suicide cases where the causal chain is established) have a separate two-year statute under Florida’s Wrongful Death Act, running from the date of death. The 90-day pre-suit investigation and § 766.102 expert affidavit requirements apply.